Physician profile
Alicia Lau
NPI 1629312210
$300,176.91
in general payments reported to CMS, 2019-2025
13 companies · $70.67 in 2025
The $70.67 reported for 2025 was less than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $481 · 2020: $125 · 2021: $382 · 2022: $37K · 2023: $148K · 2024: $114K · 2025: $70.67.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $262K · Food and Beverage: $70.67.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $262,299.60 |
| Food and Beverage | $70.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Carl Zeiss Meditec, INC. | $298,562.10 | 2022-2024 | Cirrus Hd-Oct, Clarus, Humphrey Field Analyzer (Hfa3) |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $500.38 | 2019-2021 | |
| Allergan, INC. | $254.28 | 2021-2022 | |
| Johnson & Johnson Vision Care, INC. | $247.40 | 2022 | |
| Aerie Pharmaceuticals, INC. | $122.49 | 2019 | |
| Shire North American Group INC | $120.43 | 2019 | |
| Bausch & Lomb Americas INC. | $115.76 | 2022 | |
| Visioneering Technologies, INC. | $114.15 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $42.38 | 2025 | |
| Dompe US, INC. | $28.29 | 2025 | Oxervate |
| Abbvie INC. | $27.66 | 2022 | |
| Alcon Vision LLC | $21.14 | 2022 | |
| Novartis Pharmaceuticals Corporation | $20.45 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alicia Lau listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.